Study of serum miR-518 and its correlation with inflammatory factors in patients with gestational diabetes mellitus complicated with hypertensive disorder complicating pregnancy

Objective: Gestational diabetes mellitus (GDM) and hypertensive disorder complicating pregnancy (HDCP) are common complications during pregnancy. This study estimated the correlation of serum miR-518 and inflammatory factors in GDM complicated with HDCP patients (GDM & HDCP).& nbsp;Methods: Total 240 pregnant women were enrolled, including 118 cases with GDM alone, 57 cases with GDM & HDCP, and 65 healthy pregnant women. The expressions of serum miR-518 and PPAR alpha were detected by RT-qPCR. The clinical diagnostic efficacy of miR-518 for GDM and GDM & HDCP was analyzed via ROC curve. Pearson coefficient was used to analyze the correlation between miR-518 and serum inflammatory factors (hs-CRP, IL-6, and TNF-alpha), and the relevance between peroxisome proliferator-activated receptor alpha (PPAR alpha) and serum inflammatory factors. The targeted binding of miR-518 and PPAR alpha was verified using dual-luciferase assay.& nbsp;Results: Serum miR-518 was highly-expressed in GDM and GDM & HDCP patients, but far higher in GDM & HDCP patients. Serum miR-518 level > 1.815 could assist the diagnosis of GDM (81.53% sensitivity and 100% specificity). Serum miR-518 expression was positively-correlated with serum inflammatory factors. miR-518 targeted PPAR alpha and PPAR alpha was lowly-expressed in the serum of GDM and GDM & HDCP patients. PPAR alpha was negatively-linked with serum inflammatory factors.& nbsp;Conclusion: High expression of miR-518 assists the diagnosis of GDM and GDM & HDCP, and miR-518 regulates the serum inflammatory factors by inhibiting PPAR alpha.

Automated summary

This study found that miR-518 was highly expressed in patients with gestational diabetes mellitus (GDM) and hypertensive disorder complicating pregnancy (HDCP), and it could assist in the diagnosis of these conditions. MiR-518 regulated serum inflammatory factors by inhibiting PPARα.